二代测序时代的慢性淋巴细胞白血病免疫球蛋白基因分析
综述讨论慢性淋巴细胞白血病(CLL)中免疫球蛋白重链可变区(IGHV)基因体细胞超突变(SHM)状态的传统Sanger测序与二代测序(NGS)检测,指出NGS用于IGHV SHM评估的需求增长但资源有限时是否总合理仍可争议,强调技术与数据解读标准化及新推荐和培训的必要性。
要点
- IGHV基因SHM状态是CLL风险分层和治疗决策的重要基石。
- 传统用Sanger测序确定IGHV SHM状态,NGS应用需求增长但资源有限时是否总合理仍可争议。
- 因分析影响治疗决策,NGS免疫遗传学的技术方面和数据解读标准化至关重要。
核心结论
- NGS用于IGHV SHM评估的需求增长,但资源有限实验室是否总合理仍可争议;技术与数据解读标准化及新推荐和培训需求比以往更大。
研究设计与样本
- 综述,讨论NGS用于CLL免疫遗传学分析的潜力与挑战。
主要发现
- IGHV SHM状态是CLL风险分层和治疗决策的重要基石。
- IGHV SHM状态传统由Sanger测序确定,NGS正推动免疫遗传学分析转变。
- NGS用于IGHV SHM评估的需求增长,但是否总合理仍可争议,至少需考虑资源有限实验室的财务因素。
- 因分析影响治疗决策,技术方面和数据解读的标准化变得至关重要。
- 建立新推荐并提供NGS免疫遗传学专门教育和培训的需求比以往更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Twenty years after landmark publications, there is a consensus that the somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is an important cornerstone for accurate risk stratification and therapeutic decision-making in patients with chronic lymphocytic leukemia (CLL). The IGHV SHM status has traditionally been determined by conventional Sanger sequencing. However, NGS has heralded a new era in medical diagnostics and immunogenetic analysis is following this trend. There is indeed a growing demand for shifting practice and using NGS for IGHV gene SHM assessment, although it is debatable whether it is always justifiable, at least taking into account financial considerations for laboratories with limited resources. Nevertheless, as this analysis impacts on treatment decisions, standardization of both technical aspects, and data interpretation becomes essential. Also, the need for establishing new recommendations and providing dedicated education and training on NGS-based immunogenetics is greater than ever before. Here we address potential and challenges of NGS-based immunogenetics in CLL. We are convinced that this perspective helps the hematological community to better understand the pros and cons of this new technological development for CLL patient management.
引用
- Davi F, Langerak AW, de Septenville AL, et al. Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia. 2020. PMID: 32561841. doi:10.1038/s41375-020-0923-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。